Allergan Plc (AGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
July 2018
344
About the Report
About the Report
Summary
Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women's health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.
Allergan Plc (AGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Allergan Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17
Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19
Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20
Allergan Plc, Pharmaceuticals & Healthcare, Deal Details 33
Asset Purchase 33
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 33
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 34
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 36
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For USD 55 Million 37
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 38
Venture Financing 39
Chase Pharma Raises USD12 Million in Financing Round 39
Chase Pharma Raises Additional USD0.5 Million in Venture Financing 40
Akarna Therapeutics Raises USD15 Million in Series B Financing 41
Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 42
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 43
Chase Pharma Raises USD3 Million in Venture Financing 44
RetroSense Therapeutics Raises USD6 Million in Series A Financing 45
Naurex Raises USD80 Million in Series C Venture Financing 46
Colorescience Raises USD15 Million in Series B Venture Financing 48
Chase Pharma Raises USD21 Million in Series B Financing 49
Naurex Raises USD 25 Million In Venture Financing 50
Topokine Therapeutics Raises Funds Through Venture Financing 52
Rhythm Holding Raises USD 11 Million In Venture Financing 53
Colorescience Raises USD 10 Million In Series A Financing 54
Anterios Raises USD 8.5 Million In Venture Financing 55
Anterios Raises USD 4.7 Million In Venture Financing 56
Topokine Therapeutics Raises Funds Through Venture Financing 57
Colorescience Raises USD 15 Million In Venture Financing 58
Regado Biosciences Raises USD 51 Million In Series E Financing 59
Naurex Raises USD 38 Million In Series B Financing 61
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 63
Rhythm Pharma Raises USD 33 Million In Series B Financing 65
Rhythm Pharma Raises USD 9.5 Million In Venture Financing 67
Uteron Pharma Raises USD 10.4 Million In Venture Financing 68
Regado Biosciences Raises USD 6.8 Million In Venture Financing 69
Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 70
Uteron Pharma Raises USD 19 Million In Venture Financing 71
SkinMedica Raises USD 16.8 Million In Venture Financing 72
Private Equity 73
Allergan May Divest its Women's Health Business 73
TPG Capital Acquires Aptalis Pharma from Actavis 74
Partnerships 75
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 75
Lyndra Enters into Agreement with Allergan 76
Allergan to Enter into Partnership with Target PharmaSolutions 77
Allergan Enters into Agreement with Novartis 78
Allergan Pharma Enters into Research Agreement with Editas Medicine 79
Gedeon Richter Enters into Distribution Agreement with Allergan 80
T2 Biosystems Enters into Agreement with Allergan 81
Amgen Enters into Agreement with Allergan 82
Allergan Enters into Co-Development Agreement with AstraZeneca 83
Galderma Enters into Agreement with ZELTIQ Aesthetics 84
Allergan Enters into Agreement with Rugen Therapeutics 85
Allergan Enters into Research Agreement with Humana 86
NuMedii Enters into Research Agreement with Allergan 87
Aptinyx to Enter into Research Partnership with Allergan 88
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 89
Molecular Partners Reinforces Partnership with Allergan 90
Allergan Enters into Distribution Agreement with WhanIn Pharma 91
Particle Sciences Enters Into Co-Development Agreement With Actavis 92
Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 93
Merrimack Pharma Amends Co-Development Agreement With Actavis 94
Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 95
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 96
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 97
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 98
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 99
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 100
Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 101
Allergan Exercises Option Agreement with Molecular Partners 102
American Medical Systems Enters Into Co-Development Agreement With Allergan 103
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 104
ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 105
Merger 106
Regado Biosciences Merges with Tobira Therapeutics 106
Licensing Agreements 108
Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 108
Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 109
Allergan Enters into Licensing Agreement with Assembly Biosciences 110
Allergan Enters Into Licensing Agreement With UroGen Pharma 112
Allergan Enters into Licensing Agreement with AstraZeneca 113
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 114
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 115
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 116
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 117
Allergan Amends Licensing Agreement with Heptares Therapeutics 118
Rhythm Pharma Enters into Licensing Agreement with Camurus 119
Allergan Enters into Licensing Agreement with Mimetogen Pharma 120
Allergan Enters into Licensing Agreement with Almirall for Constella 121
Apricus Biosciences Enters into Licensing Agreement with Allergan 122
Allergan Enters into Licensing Agreement with Merck 123
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 124
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 125
Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 126
Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 127
RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 128
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 129
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 130
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 131
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 132
Angelini Enters into Licensing Agreement with Allergan 133
Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 134
InnoCore Enters Into Licensing Agreement With Allergan 135
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 136
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 137
Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 138
Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 139
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 140
QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 141
Equity Offering 143
Allergan Files Registration Statement for Public Offering of Securities 143
Vitae Pharma Raises USD35 Million in Public Offering of Shares 144
Aptinyx Spin Off from Naurex 146
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 147
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 148
Anterios Postpones IPO for up to USD54.6 Million 149
Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 150
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 152
Actavis Raises USD4.18 Billion in Public Offering of Shares 154
Vitae Pharma Raises USD41 Million in Public Offering of Shares 156
Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 158
Tobira Therapeutics Withdraws IPO 160
Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 162
Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 164
Furiex Pharma Files Registration Statement For Public Offering Of Securities For USD 100 Million 165
Kythera Biopharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 133.5 Million 166
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 168
Durata Therapeutics Completes Public Offering Of Shares For USD 58 Million 170
Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 81 Million 172
MAP Pharma Completes Public Offering Of Common Stock For USD 60 Million 174
Forest Labs Plans Rights Offering Of Common Stock 175
Durata Therapeutics Completes IPO For USD 78 Million 176
Debt Offering 178
Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 178
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 179
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 180
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 181
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 182
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 183
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 185
Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 187
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 189
Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 191
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 193
Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 195
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 197
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 199
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 201
Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 203
Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 204
Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 205
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD 25 Million 206
Watson Pharma Completes Public Offering Of Notes Due 2022 For USD 1.7 Billion 207
Watson Pharma Completes Public Offering Of Notes Due 2017 For USD 1.2 Billion 209
Watson Pharma Completes Public Offering Of Notes Due 2042 For USD 1 Billion 211
Asset Transactions 213
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 213
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 215
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 217
Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 219
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 220
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 221
Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 222
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 223
Impax Labs Acquires Two Generic Products from Actavis 224
G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 225
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 226
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 228
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 229
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 231
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 233
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 234
Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For USD 117 Million 236
Acquisition 238
Allergan May Acquire Kandy Therapeutics 238
Allergan to Acquire Repros Therapeutics in Tender Offer 239
Allergan to Sell 10% Stake in Teva Pharma 241
Adcock Ingram to Acquire Genop 242
Paratek Pharma May Sell Itself 243
Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 245
Allergan Acquires Motus Therapeutics 246
Allergan Acquires Chase Pharma 247
Allergan Acquires Tobira Therapeutics in Tender Offer 248
Allergan Acquires Vitae Pharma in Tender Offer 250
Teva Pharma Acquires Anda from Allergan for USD500 Million 252
Allergan Acquires ForSight VISION5 253
Allergan Acquires RetroSense Therapeutics 254
Allergan Acquires Akarna Therapeutics 255
Carl Icahn Acquires Stake in Allergan 256
Allergan Acquires Topokine Therapeutics 257
Allergan Acquires Anterios 258
Allergan Acquires Kythera Biopharma for USD2.1 Billion 259
Allergan Acquires Naurex 261
Actavis Acquires Auden Mckenzie for USD458 Million 262
Actavis Acquires Allergan for USD70.5 Billion 263
Actavis May Acquire Almirall 265
Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 266
Pfizer May Acquire Actavis 268
Forest Labs Completes Acquisition of Furiex Pharma 269
Actavis Completes Acquisition of Forest Labs for USD28 Billion 271
Actavis Acquires Silom Medical For USD 100 Million 273
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 274
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 276
Actavis Completes Acquisition Of Warner Chilcott For USD 8.5 Billion 277
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 280
Allergan Completes Acquisition Of MAP Pharma For USD 958 Million 281
Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 283
Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For USD 350 Million 285
Watson Pharma Completes Acquisition Of Actavis Group For USD 5.92 Billion 287
Watson Pharma Sells Minority Stake In moksha8 Pharma For USD 47 Million 289
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For USD 394 Million 290
SkinMedica Acquires Colorescience, Maker Of Skincare Products 292
Allergan Plc - Key Competitors 293
Allergan Plc - Key Employees 294
Allergan Plc - Locations And Subsidiaries 295
Head Office 295
Other Locations & Subsidiaries 295
Recent Developments 303
Financial Announcements 303
Apr 30, 2018: Allergan Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 Billion 303
Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference 306
Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion 307
Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 311
May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 315
Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 319
Corporate Communications 323
Jun 14, 2018: Allergan Continues Active Board Refreshment Process 323
May 03, 2018: John Davidson Elected to Allergan Board of Directors 324
Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer 325
Jan 04, 2018: Allergan to cut over 1,000 jobs to reduce costs 326
Sep 25, 2017: Allergan Announces Tessa Hilado, Executive Vice President and Chief Financial Officer, to Retire from Company 327
Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 328
Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 329
Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 330
Legal and Regulatory 331
Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 331
Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber's Choice and Sincerus Florida 332
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 333
Government and Public Interest 334
Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 334
Feb 21, 2018: New report shines light on disconnect between patient and physicians when it comes to the seriousness of IBS, leading to slow diagnosis 336
Jan 23, 2017: Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists 337
Product News 338
Jul 10, 2018: Allergan Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops 338
05/01/2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 339
Product Approvals 340
Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan 340
Other Significant Developments 341
May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 341
Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 342
Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 343
Appendix 344
Methodology 344
About GlobalData 344
Contact Us 344
Disclaimer 344
List of Figure
List of Figures
Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 15
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17
Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19
List of Table
List of Tables
Allergan Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Allergan Plc, Deals By Therapy Area, 2012 to YTD 2018 17
Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19
Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 33
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 34
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 36
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For USD 55 Million 37
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 38
Chase Pharma Raises USD12 Million in Financing Round 39
Chase Pharma Raises Additional USD0.5 Million in Venture Financing 40
Akarna Therapeutics Raises USD15 Million in Series B Financing 41
Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 42
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 43
Chase Pharma Raises USD3 Million in Venture Financing 44
RetroSense Therapeutics Raises USD6 Million in Series A Financing 45
Naurex Raises USD80 Million in Series C Venture Financing 46
Colorescience Raises USD15 Million in Series B Venture Financing 48
Chase Pharma Raises USD21 Million in Series B Financing 49
Naurex Raises USD 25 Million In Venture Financing 50
Topokine Therapeutics Raises Funds Through Venture Financing 52
Rhythm Holding Raises USD 11 Million In Venture Financing 53
Colorescience Raises USD 10 Million In Series A Financing 54
Anterios Raises USD 8.5 Million In Venture Financing 55
Anterios Raises USD 4.7 Million In Venture Financing 56
Topokine Therapeutics Raises Funds Through Venture Financing 57
Colorescience Raises USD 15 Million In Venture Financing 58
Regado Biosciences Raises USD 51 Million In Series E Financing 59
Naurex Raises USD 38 Million In Series B Financing 61
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 63
Rhythm Pharma Raises USD 33 Million In Series B Financing 65
Rhythm Pharma Raises USD 9.5 Million In Venture Financing 67
Uteron Pharma Raises USD 10.4 Million In Venture Financing 68
Regado Biosciences Raises USD 6.8 Million In Venture Financing 69
Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 70
Uteron Pharma Raises USD 19 Million In Venture Financing 71
SkinMedica Raises USD 16.8 Million In Venture Financing 72
Allergan May Divest its Women's Health Business 73
TPG Capital Acquires Aptalis Pharma from Actavis 74
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 75
Lyndra Enters into Agreement with Allergan 76
Allergan to Enter into Partnership with Target PharmaSolutions 77
Allergan Enters into Agreement with Novartis 78
Allergan Pharma Enters into Research Agreement with Editas Medicine 79
Gedeon Richter Enters into Distribution Agreement with Allergan 80
T2 Biosystems Enters into Agreement with Allergan 81
Amgen Enters into Agreement with Allergan 82
Allergan Enters into Co-Development Agreement with AstraZeneca 83
Galderma Enters into Agreement with ZELTIQ Aesthetics 84
Allergan Enters into Agreement with Rugen Therapeutics 85
Allergan Enters into Research Agreement with Humana 86
NuMedii Enters into Research Agreement with Allergan 87
Aptinyx to Enter into Research Partnership with Allergan 88
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 89
Molecular Partners Reinforces Partnership with Allergan 90
Allergan Enters into Distribution Agreement with WhanIn Pharma 91
Particle Sciences Enters Into Co-Development Agreement With Actavis 92
Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 93
Merrimack Pharma Amends Co-Development Agreement With Actavis 94
Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 95
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 96
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 97
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 98
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 99
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 100
Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 101
Allergan Exercises Option Agreement with Molecular Partners 102
American Medical Systems Enters Into Co-Development Agreement With Allergan 103
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 104
ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 105
Regado Biosciences Merges with Tobira Therapeutics 106
Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 108
Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 109
Allergan Enters into Licensing Agreement with Assembly Biosciences 110
Allergan Enters Into Licensing Agreement With UroGen Pharma 112
Allergan Enters into Licensing Agreement with AstraZeneca 113
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 114
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 115
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 116
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 117
Allergan Amends Licensing Agreement with Heptares Therapeutics 118
Rhythm Pharma Enters into Licensing Agreement with Camurus 119
Allergan Enters into Licensing Agreement with Mimetogen Pharma 120
Allergan Enters into Licensing Agreement with Almirall for Constella 121
Apricus Biosciences Enters into Licensing Agreement with Allergan 122
Allergan Enters into Licensing Agreement with Merck 123
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 124
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 125
Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 126
Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 127
RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 128
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 129
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 130
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 131
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 132
Angelini Enters into Licensing Agreement with Allergan 133
Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 134
InnoCore Enters Into Licensing Agreement With Allergan 135
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 136
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 137
Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 138
Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 139
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 140
QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 141
Allergan Files Registration Statement for Public Offering of Securities 143
Vitae Pharma Raises USD35 Million in Public Offering of Shares 144
Aptinyx Spin Off from Naurex 146
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 147
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 148
Anterios Postpones IPO for up to USD54.6 Million 149
Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 150
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 152
Actavis Raises USD4.18 Billion in Public Offering of Shares 154
Vitae Pharma Raises USD41 Million in Public Offering of Shares 156
Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 158
Tobira Therapeutics Withdraws IPO 160
Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 162
Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 164
Furiex Pharma Files Registration Statement For Public Offering Of Securities For USD 100 Million 165
Kythera Biopharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 133.5 Million 166
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 168
Durata Therapeutics Completes Public Offering Of Shares For USD 58 Million 170
Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 81 Million 172
MAP Pharma Completes Public Offering Of Common Stock For USD 60 Million 174
Forest Labs Plans Rights Offering Of Common Stock 175
Durata Therapeutics Completes IPO For USD 78 Million 176
Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 178
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 179
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 180
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 181
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 182
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 183
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 185
Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 187
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 189
Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 191
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 193
Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 195
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 197
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 199
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 201
Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 203
Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 204
Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 205
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD 25 Million 206
Watson Pharma Completes Public Offering Of Notes Due 2022 For USD 1.7 Billion 207
Watson Pharma Completes Public Offering Of Notes Due 2017 For USD 1.2 Billion 209
Watson Pharma Completes Public Offering Of Notes Due 2042 For USD 1 Billion 211
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 213
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 215
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 217
Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 219
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 220
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 221
Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 222
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 223
Impax Labs Acquires Two Generic Products from Actavis 224
G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 225
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 226
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 228
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 229
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 231
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 233
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 234
Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For USD 117 Million 236
Allergan May Acquire Kandy Therapeutics 238
Allergan to Acquire Repros Therapeutics in Tender Offer 239
Allergan to Sell 10% Stake in Teva Pharma 241
Adcock Ingram to Acquire Genop 242
Paratek Pharma May Sell Itself 243
Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 245
Allergan Acquires Motus Therapeutics 246
Allergan Acquires Chase Pharma 247
Allergan Acquires Tobira Therapeutics in Tender Offer 248
Allergan Acquires Vitae Pharma in Tender Offer 250
Teva Pharma Acquires Anda from Allergan for USD500 Million 252
Allergan Acquires ForSight VISION5 253
Allergan Acquires RetroSense Therapeutics 254
Allergan Acquires Akarna Therapeutics 255
Carl Icahn Acquires Stake in Allergan 256
Allergan Acquires Topokine Therapeutics 257
Allergan Acquires Anterios 258
Allergan Acquires Kythera Biopharma for USD2.1 Billion 259
Allergan Acquires Naurex 261
Actavis Acquires Auden Mckenzie for USD458 Million 262
Actavis Acquires Allergan for USD70.5 Billion 263
Actavis May Acquire Almirall 265
Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 266
Pfizer May Acquire Actavis 268
Forest Labs Completes Acquisition of Furiex Pharma 269
Actavis Completes Acquisition of Forest Labs for USD28 Billion 271
Actavis Acquires Silom Medical For USD 100 Million 273
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 274
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 276
Actavis Completes Acquisition Of Warner Chilcott For USD 8.5 Billion 277
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 280
Allergan Completes Acquisition Of MAP Pharma For USD 958 Million 281
Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 283
Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For USD 350 Million 285
Watson Pharma Completes Acquisition Of Actavis Group For USD 5.92 Billion 287
Watson Pharma Sells Minority Stake In moksha8 Pharma For USD 47 Million 289
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For USD 394 Million 290
SkinMedica Acquires Colorescience, Maker Of Skincare Products 292
Allergan Plc, Key Competitors 293
Allergan Plc, Key Employees 294
Allergan Plc, Other Locations 295
Allergan Plc, Subsidiaries 295
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.